Benitec Biopharma (BNTC) Competitors $12.66 +0.15 (+1.20%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$12.68 +0.02 (+0.16%) As of 08/14/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BNTC vs. HROW, PRAX, AVDL, PAHC, PHVS, ARDX, GPCR, AMPH, VERV, and SYREShould you be buying Benitec Biopharma stock or one of its competitors? The main competitors of Benitec Biopharma include Harrow (HROW), Praxis Precision Medicines (PRAX), Avadel Pharmaceuticals (AVDL), Phibro Animal Health (PAHC), Pharvaris (PHVS), Ardelyx (ARDX), Structure Therapeutics (GPCR), Amphastar Pharmaceuticals (AMPH), Verve Therapeutics (VERV), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry. Benitec Biopharma vs. Its Competitors Harrow Praxis Precision Medicines Avadel Pharmaceuticals Phibro Animal Health Pharvaris Ardelyx Structure Therapeutics Amphastar Pharmaceuticals Verve Therapeutics Spyre Therapeutics Benitec Biopharma (NASDAQ:BNTC) and Harrow (NASDAQ:HROW) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment. Is BNTC or HROW more profitable? Benitec Biopharma has a net margin of 0.00% compared to Harrow's net margin of -4.49%. Harrow's return on equity of -2.18% beat Benitec Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Benitec BiopharmaN/A -38.26% -35.71% Harrow -4.49%-2.18%-0.35% Does the media prefer BNTC or HROW? In the previous week, Harrow had 22 more articles in the media than Benitec Biopharma. MarketBeat recorded 26 mentions for Harrow and 4 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 1.35 beat Harrow's score of 0.69 indicating that Benitec Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Benitec Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Harrow 3 Very Positive mention(s) 2 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, BNTC or HROW? Harrow has higher revenue and earnings than Benitec Biopharma. Harrow is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBenitec Biopharma$80K4,154.06-$21.75M-$1.51-8.38Harrow$199.61M7.42-$17.48M-$0.25-160.04 Which has more volatility & risk, BNTC or HROW? Benitec Biopharma has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500. Comparatively, Harrow has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Do insiders & institutionals have more ownership in BNTC or HROW? 52.2% of Benitec Biopharma shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 1.3% of Benitec Biopharma shares are owned by company insiders. Comparatively, 15.2% of Harrow shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts rate BNTC or HROW? Benitec Biopharma currently has a consensus target price of $26.00, suggesting a potential upside of 105.37%. Harrow has a consensus target price of $64.67, suggesting a potential upside of 61.63%. Given Benitec Biopharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Benitec Biopharma is more favorable than Harrow.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Benitec Biopharma 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Harrow 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryHarrow beats Benitec Biopharma on 9 of the 16 factors compared between the two stocks. Get Benitec Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BNTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BNTC vs. The Competition Export to ExcelMetricBenitec BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$328.39M$3.10B$5.61B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-8.3820.4930.2725.74Price / Sales4,154.06356.37459.75115.79Price / CashN/A43.0338.2159.48Price / Book2.718.608.846.15Net Income-$21.75M-$54.65M$3.25B$265.06M7 Day Performance7.29%5.86%3.72%2.60%1 Month Performance1.77%8.86%5.86%2.83%1 Year Performance47.21%13.33%30.25%25.58% Benitec Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BNTCBenitec Biopharma1.7869 of 5 stars$12.66+1.2%$26.00+105.4%+45.0%$328.39M$80K-8.3820News CoveragePositive NewsHROWHarrow2.6358 of 5 stars$33.42+7.0%$63.83+91.0%+8.0%$1.15B$199.61M-59.68180Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionPRAXPraxis Precision Medicines1.8554 of 5 stars$51.09-5.5%$94.11+84.2%-6.9%$1.10B$8.55M-4.77110High Trading VolumeAVDLAvadel Pharmaceuticals2.9304 of 5 stars$11.26+1.6%$18.33+62.8%-14.2%$1.07B$169.12M-41.7070Positive NewsPAHCPhibro Animal Health3.7187 of 5 stars$27.14+3.9%$24.40-10.1%+75.8%$1.06B$1.02B34.801,940Gap DownPHVSPharvaris2.4162 of 5 stars$21.24+6.2%$36.20+70.4%+36.0%$1.05BN/A-7.0630News CoverageEarnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionARDXArdelyx4.4265 of 5 stars$4.39+1.4%$10.88+147.7%+2.8%$1.04B$333.61M-19.9590Options VolumeGPCRStructure Therapeutics2.4785 of 5 stars$16.78-4.6%$76.17+353.9%-48.9%$1.01BN/A-19.29136AMPHAmphastar Pharmaceuticals3.1988 of 5 stars$21.40+0.9%$32.33+51.1%-28.8%$999.82M$731.97M7.752,028Analyst UpgradeVERVVerve Therapeutics2.9506 of 5 stars$11.13flat$14.57+30.9%N/A$992.13M$32.33M-5.27110SYRESpyre Therapeutics3.1061 of 5 stars$16.16-0.6%$53.40+230.4%-31.8%$980.08M$890K-4.2973Positive NewsGap Down Related Companies and Tools Related Companies HROW Alternatives PRAX Alternatives AVDL Alternatives PAHC Alternatives PHVS Alternatives ARDX Alternatives GPCR Alternatives AMPH Alternatives VERV Alternatives SYRE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BNTC) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Benitec Biopharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Benitec Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access